Market Cap 18.55M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio -0.36
Volume 47,848,402
Avg Vol 124,226,063
Day's Range N/A - N/A
Shares Out 265.05M
Stochastic %K 12%
Beta 2.49
Analysts Hold
Price Target $0.52

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
CATatom
CATatom Oct. 25 at 1:49 PM
$ADAP T-cell pipeline still intact. Patents still active. Trials paused, not canceled. Delisting ≠ death. OTC opens Tuesday. Monday’s candle decides who believed early. ADAP will stop trading on the Nasdaq Capital Market after the close of trading on October 27, 2025. Starting October 28, 2025, its American Depositary Shares (ADSs) will be quoted on the OTC Pink Limited Market. Science doesn’t care about Nasdaq. Shorts played the fade. But they didn’t cover. Monday’s volume spike could trigger a reflexive squeeze.
3 · Reply
HellasManN10
HellasManN10 Oct. 25 at 1:48 PM
$ADAP In my humble opinion, the voluntary abandonment of the Nasdaq could have been due to a combination of factors (need to save on costs, obligations, constraints, etc.) assuming a final solution such as a sale or merger, in the OTC the company probably she wanted to distance herself to feel freer about 1) HOW to proceed (with whom and in what manner) 2) HOW MUCH to sell and, above all 3) WHEN ... the timing factor is important ... === 》I have kept all my many shares
0 · Reply
SMARTR8
SMARTR8 Oct. 25 at 1:43 PM
🚨 If you’re still only following me here, you’re missing out. The real plays, live discussions, and updates all happen inside the Discord — before anything ever gets posted on Stocktwits. THIS WEEK $SCNX from 0.56 to 2.98 $VSEE from 0.56 to 1.18 $ADAP from 0.05 to 0.092 - all shared for FREE We’re even running a Stock Pick Challenge this week — someone’s walking away with free VIP Vault access 💎. If you’re serious about trading smart, you’ll want to be in there before the next wave hits. 👉 Link in bio
0 · Reply
Gamaret
Gamaret Oct. 25 at 1:27 PM
0 · Reply
FlyAlways
FlyAlways Oct. 25 at 12:38 PM
$ADAP has the potential for explosive moves 🧨
1 · Reply
US_Bull
US_Bull Oct. 25 at 12:27 PM
$ADAP Misery loves company those who bash and talk down the stock are the ones that sold at a 6-70% loss when they released the PR so they bought high and sold low lol. Company has hit the reset button, paid all debts, has a very promising preclinical pipeline in CD70 and PRAME and allogenic technology, and most importantly has the IP and know how to take the sold assets to approval. USWorldmed needs that know how still little grey area what happens to their PS with GLPG. I am assuming that PS may be put on a backburner as well since GLPG is winding down their cell therapy pipeline. A delisting of the stock is not the same as a company going bankrupt shocking how people are investing with their hard earned $ lol.
1 · Reply
Gamaret
Gamaret Oct. 25 at 9:49 AM
0 · Reply
Gamaret
Gamaret Oct. 25 at 9:33 AM
$ADAP Consider the example of SPRB Spruce Biosciences, Inc.
0 · Reply
Gamaret
Gamaret Oct. 25 at 9:28 AM
$ADAP Someone mentioned SPRB stock, which also ended up on the OTC market. I did some research: Spruce Biosciences, Inc.'s stock rose sharply after the FDA granted its drug Breakthrough Therapy Designation in October 2025. This designation allowed the company to move from an over-the-counter (OTC) listing to a listing on the Nasdaq Capital Market, which led to a sharp rise in the stock price due to investor optimism.
1 · Reply
stockCryptoHunter
stockCryptoHunter Oct. 24 at 11:51 PM
$ADAP Monday will be interesting .
1 · Reply
Latest News on ADAP
Adaptimmune Announces Delisting from Nasdaq

Oct 20, 2025, 7:40 AM EDT - 5 days ago

Adaptimmune Announces Delisting from Nasdaq


Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update


Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Adaptimmune Reports Q3 2024 Financial and Business Updates


Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates


Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates


Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech


Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 2 years ago

Adaptimmune Receives Transfer of IND for Lete-cel Program


CATatom
CATatom Oct. 25 at 1:49 PM
$ADAP T-cell pipeline still intact. Patents still active. Trials paused, not canceled. Delisting ≠ death. OTC opens Tuesday. Monday’s candle decides who believed early. ADAP will stop trading on the Nasdaq Capital Market after the close of trading on October 27, 2025. Starting October 28, 2025, its American Depositary Shares (ADSs) will be quoted on the OTC Pink Limited Market. Science doesn’t care about Nasdaq. Shorts played the fade. But they didn’t cover. Monday’s volume spike could trigger a reflexive squeeze.
3 · Reply
HellasManN10
HellasManN10 Oct. 25 at 1:48 PM
$ADAP In my humble opinion, the voluntary abandonment of the Nasdaq could have been due to a combination of factors (need to save on costs, obligations, constraints, etc.) assuming a final solution such as a sale or merger, in the OTC the company probably she wanted to distance herself to feel freer about 1) HOW to proceed (with whom and in what manner) 2) HOW MUCH to sell and, above all 3) WHEN ... the timing factor is important ... === 》I have kept all my many shares
0 · Reply
SMARTR8
SMARTR8 Oct. 25 at 1:43 PM
🚨 If you’re still only following me here, you’re missing out. The real plays, live discussions, and updates all happen inside the Discord — before anything ever gets posted on Stocktwits. THIS WEEK $SCNX from 0.56 to 2.98 $VSEE from 0.56 to 1.18 $ADAP from 0.05 to 0.092 - all shared for FREE We’re even running a Stock Pick Challenge this week — someone’s walking away with free VIP Vault access 💎. If you’re serious about trading smart, you’ll want to be in there before the next wave hits. 👉 Link in bio
0 · Reply
Gamaret
Gamaret Oct. 25 at 1:27 PM
0 · Reply
FlyAlways
FlyAlways Oct. 25 at 12:38 PM
$ADAP has the potential for explosive moves 🧨
1 · Reply
US_Bull
US_Bull Oct. 25 at 12:27 PM
$ADAP Misery loves company those who bash and talk down the stock are the ones that sold at a 6-70% loss when they released the PR so they bought high and sold low lol. Company has hit the reset button, paid all debts, has a very promising preclinical pipeline in CD70 and PRAME and allogenic technology, and most importantly has the IP and know how to take the sold assets to approval. USWorldmed needs that know how still little grey area what happens to their PS with GLPG. I am assuming that PS may be put on a backburner as well since GLPG is winding down their cell therapy pipeline. A delisting of the stock is not the same as a company going bankrupt shocking how people are investing with their hard earned $ lol.
1 · Reply
Gamaret
Gamaret Oct. 25 at 9:49 AM
0 · Reply
Gamaret
Gamaret Oct. 25 at 9:33 AM
$ADAP Consider the example of SPRB Spruce Biosciences, Inc.
0 · Reply
Gamaret
Gamaret Oct. 25 at 9:28 AM
$ADAP Someone mentioned SPRB stock, which also ended up on the OTC market. I did some research: Spruce Biosciences, Inc.'s stock rose sharply after the FDA granted its drug Breakthrough Therapy Designation in October 2025. This designation allowed the company to move from an over-the-counter (OTC) listing to a listing on the Nasdaq Capital Market, which led to a sharp rise in the stock price due to investor optimism.
1 · Reply
stockCryptoHunter
stockCryptoHunter Oct. 24 at 11:51 PM
$ADAP Monday will be interesting .
1 · Reply
Thunder000
Thunder000 Oct. 24 at 11:31 PM
$ASST $VIVK $ADAP CLIK is running but I’d say no to Chinese Hong Kong companies, I chose to stick with American dear darling lovely ones💪
0 · Reply
Wildblitz
Wildblitz Oct. 24 at 11:27 PM
$ADAP $HCTI $TELO - my 3 craptastic stocks of the week
0 · Reply
btball64
btball64 Oct. 24 at 10:32 PM
$ADAP Will there be a new stock ticker on Monday?
1 · Reply
berat2209
berat2209 Oct. 24 at 10:14 PM
$ADAP do you think US WorldMeds will acquire this company
2 · Reply
RedHottie
RedHottie Oct. 24 at 9:36 PM
$ADAP nice candle
1 · Reply
RedHottie
RedHottie Oct. 24 at 9:29 PM
$ADAP Green 🤗
0 · Reply
RedHottie
RedHottie Oct. 24 at 9:18 PM
$ADAP OK I might be an addict lol but I just bought another 50,000 shares 🤗💰
2 · Reply
Tomc73
Tomc73 Oct. 24 at 9:08 PM
$ADAP monday will be good
1 · Reply
Herre62
Herre62 Oct. 24 at 9:02 PM
$ADAP Have a good weekends , I will catch you guys on premarket on Sunday nights …
1 · Reply
Bottomdog
Bottomdog Oct. 24 at 8:53 PM
0 · Reply
stocktraderbegins
stocktraderbegins Oct. 24 at 8:48 PM
$ADAP Are my options done if this hits OTC ?
2 · Reply
maniamedmao
maniamedmao Oct. 24 at 8:35 PM
$ADAP I told you so, but bravo to those who believe in poop creating flowers until the end ! You showed determination and I respect that, now if you get equity from this delisting that good bc equity is better than that stocks
0 · Reply